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Receptor Signaling via Brainstem 
Catecholamine Neurons 
Counteracts Hypertension in 
Spontaneously Hypertensive Rats
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Glucagon-like peptide-1 (GLP-1) related medicines are widely used to treat type-2 diabetic patients. Recently, car-
diovascular outcome study of GLP-1 receptor (GLP-1R) agonists showed reduction of cardiovascular events and 
prevention of chronic kidney disease progression in type-2 diabetic patients1–3. Studies in hypertensive patients 
with type-2 diabetes showed that long-term treatment with GLP-1R agonists reduced blood pressure (BP)4–10. 
!is antihypertensive e"ect of GLP-1R agonists might contribute to the ability of these medicines to protect the 
cardiovascular system.
Several possible mechanisms for antihypertensive e"ect of GLP-1R agonists have been postulated. GLP-1R 
agonist directly acts on the kidney to induce natriuresis11–14, on the endothelial cells to induce vasodilatation12,15, 
and on the atrial cardiomyocytes to induce secretion of atrial natriuretic peptide16. In addition to these direct 
e"ects on the end e"ectors, GLP-1 may also regulate BP via the central action. GLP-1Rs are expressed in the 
hypothalamus and brainstem regions implicated in sympathetic and cardiovascular control17,18. GLP-1R agonists 
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can pass the blood brain barrier19–21. However, the mechanisms underlying the central action of GLP-1R agonists 
to lower BP remain to be fully elucidated.
To date there have been two clinical trials showing suppression of cardiovascular events in type 2 diabetic 
patients treated with GLP-1R agonists, LEADER3 and SUSTAIN-62 trials. In LEADER trial, GLP-1R agonist, 
liraglutide signi#cantly decreases systolic BP (SBP) by −1.2 mmHg and suppresses death from cardiovascular 
causes. In SUSTAIN-6 trial, another GLP-1R agonist, semaglutide that has same amino-acid sequences as lira-
glutide signi#cantly decreases SBP by −3.4 to −5.4 mmHg and suppresses nonfatal stroke. It is well known that 
development and progression of cardiovascular disease is strongly associated with sympathetic hyperactivity and 
treatment with sympathoinhibition probably leads to suppression of cardiovascular events22,23. Further, these 
strong and de#nite cardiovascular e"ects of liraglutide could be independent on the glucose lowering and associ-
ated e"ects. Based on these results form LEADER and SUSTAIN-6 trials we hypothesized that liraglutide exhibits 
antihypertensive e"ect accompanied with sympathoinhibition leading to suppression of cardiovascular events.
To test this hypothesis we assessed the central action of liraglutide and underlying mechanism to counteract 
hypertension in spontaneously hypertensive rat (SHR) that has hypertensive and sympathoexcitative proper-
ties. We performed intracerebroventricular (icv) injection of liraglutide (0.9 µg/3 µl) once daily for 15 days, and 
investigated its e"ect on urinary norepinephrine excretion, as a marker of systemic sympathetic nerve activity, 
and on c-Fos expression in the hypothalamus and brainstem of central nervous system (CNS) as a marker for 
neuronal activity in the CNS. To gain further insight into the central neuron mediating the GLP-1 action, we 
focused on the nucleus tractus solitarius (NTS) catecholamine neurons expressing dopamine beta-hydroxylase 
(DBH), since DBH converts dopamine to norepinephrine and the NTS DBH neuron is implicated in regulation 
of cardiovascular functions. It has been reported that reduced DBH activity in the brain is linked to an increase in 
blood pressure24–27, and that lesion of NTS DBH neurons induces barore$ex dysfunction and liability for BP28,29. 
To delete NTS catecholamine neurons, we injected the saporin-conjugate antibody to DBH (anti-DBH-SAP) into 
NTS bilaterally and investigated whether the e"ect of icv liraglutide on BP is a"ected.
We found that repeated lateral ventricular (LV) injection of liraglutide counteracted the development of 
hypertension and suppressed sympathetic nerve activity. Fourth ventricular (4V) injection of liraglutide acutely 
decreased BP. !e lesion of NTS DBH neurons by anti-DBH-SAP attenuated both acute depressor e"ect of 4V 
injection of liraglutide and chronic antihypertensive e"ect of LV injection of liraglutide.
Results
Ǥ SBP in 
SHR signi#cantly increased during the 15 days period. Repeated LV injection of liraglutide (0.9 µg/3 µl) once a day 
attenuated the increase of SBP in SHR at 15 days of injection, and had no e"ect on SBP in control Wister Kyoto 
(WKY) rats (Fig. 1A). Administration of liraglutide did not in$uence heart rate (HR) in both SHR and WKY rats 
during the 15 days period (Fig. 1B). In the pair feeding study, the pair-fed saline injected SHR exhibited signi#-
cant increase in SBP during the 14 days period, similar to the saline injected SHR without pair feeding (Fig. 1C). 
Repeated LV injection of liraglutide counteracted the increase in SBP in SHR at 14 days of injection (Fig. 1C).
Ǥ !e urinary norep-
inephrine excretion was measured at 14 days of repeated LV injection of liraglutide or saline. !e urinary norepi-
nephrine excretion was signi#cantly elevated in SHR compared to WKY rats, and this elevation was signi#cantly 
attenuated by liraglutide administration (Fig. 2A). In the pair feeding study, the pair-fed saline injected SHR 
exhibited signi#cant increase in norepinephrine excretion (Fig. 2B) to a level similar to that in the saline injected 
SHR without pair feeding (Fig. 2A). Repeated LV injection of liraglutide signi#cantly suppressed the norepineph-
rine excretion in SHR compared to pair-fed saline injected SHR at 14 days of injection (Fig. 2B).
Ǧ	Ǥ To explore the brain regions tar-
geted by liraglutide, c-Fos expression in the brain was investigated at four hours a&er LV injection of liraglutide 
on the #rst day of experiment. LV injection of liraglutide, compared to saline, signi#cantly increased c-Fos expres-
sion in the paraventricular nucleus (PVN) and arcuate nucleus (ARC) in hypothalamus and area postrema (AP) 
and NTS in brainstem in both SHR and WKY rats (Fig. 3A–G). Later, on one day a&er termination of repeated 
LV injection of liraglutide for 14 days, LV injection of liraglutide signi#cantly increased c-Fos expression in the 
AP and NTS in brainstem, while that in hypothalamic PVN and ARC was unaltered in both SHR and WKY rats 
(Fig. 3H–M). !e number of c-Fos positive cells in the AP and NTS were around 2-fold more in SHR than in 
WKY rats at 14 days of treatment with liraglutide (Fig. 3N). !us, LV injection of liraglutide induced antihyper-
tensive e"ect and c-Fos expression in the AP and NTS at 15 days in SHR.
Ǧ	Ǥ To 
assess the area in the brain targeted by peripheral injection of liraglutide, as well as LV injection of it, c-Fos 
expression in the brain was investigated at four hours a&er intraperitoneal (IP) injection of liraglutide both before 
and a&er repeated IP injection of liraglutide once a day for 14 days. !e #rst IP injection of liraglutide increased 
c-Fos expression in PVN, ARC, AP and NTS in SHR (Fig. 4A–D). A&er treatment with liraglutide by repeated IP 
injection for 14 days, the next IP injection of liraglutide increased c-Fos expression in AP and NTS, but not PVN 
and ARC (Fig. 4E–H).
ͺǤ !ese results prompted us to 
hypothesize that liraglutide acts on the AP and/or NTS to counteract hypertension in SHR. Hence, we performed 
acute administration of liraglutide into 4V, the area with easy access to the AP and NTS, and it decreased the 
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blood pressure measured intra-arterially in anesthetized SHR (Fig. 5A). !e change took transient pattern, and 
the peak change in average of mean arterial pressure (MAP) was −6.0 ± 2.1 mmHg (Fig. 5C). In contrast, 4V 
injection of liraglutide had no e"ect on HR (Fig. 5B,D).
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Figure 1. Repeated LV injection of liraglutide attenuates development of hypertension in SHR. E"ect of 
repeated LV injection of 0.9 µg liraglutide or saline once a day for 15 days on systolic blood pressure (A) 
and heart rate (B) in SHR (n = 5) and WKY rats (n = 5–6), and systolic blood pressure (C) in liraglutide-
injected SHR (n = 5) and saline-injected SHR pair-fed to liraglutide-injected group (n = 5). Data are shown as 
mean ± SE. *P < 0.05 between liraglutide and saline groups by repeated measures two-way ANOVA followed 
by Turkey’s post hoc test. Figure A (SHR): P value for time, group and time x group interaction are p < 0.0001, 
p = 0.0409 and p = 0.0301, respectively. Figure C: P value for time, group and time x group interaction are 
p < 0.0001, p = 0.7918 and p = 0.0045, respectively.
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Figure 2. Repeated LV liraglutide suppresses urinary norepinephrine excretion in SHR. E"ect of repeated LV 
injection of liraglutide for 14 days on the 24 hour urinary norepinephrine excretion in SHR and WKY rats (A, 
n = 5), and in liraglutide-injected SHR and saline-injected SHR pair-fed to liraglutide-injected rats (B, n = 5). 
*P < 0.05 between liraglutide and saline. #P < 0.05 between WKY with saline and SHR with saline.
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Ǥ !e NTS is one of key centers for cardiovascu-
lar control, where DBH neurons play important roles in homeostatic regulation of BP including barore$ex. We 
focused on the relationship between BP control and NTS DBH neurons under LV injection of liraglutide. We 
performed double immunostaining for c-Fos and DBH in the NTS in SHR a&er LV injection of liraglutide on 
both the #rst day and one day a&er termination of repeated LV injection of liraglutide for 14 days. LV injection 
of liraglutide, compared to saline, signi#cantly increased c-Fos expression in NTS DBH neurons both before and 
a&er repeated LV injection of liraglutide (Fig. 6). A&er repeated LV injection of liraglutide, 12.9% of DBH neurons 
were c-Fos-immoreacitive (IR) in liraglutide group compared with 1.8% in control group (p < 0.05, Fig. 6I). !e 
fraction of DBH-IR neurons among the c-Fos-IR neurons was signi#cantly increased by liraglutide administra-
tion (14.2% in liraglutide group vs. 6.3% in control group, p < 0.05) (Fig. 6J). !ese results show that LV injection 
of liraglutide speci#cally and substantially activates NTS DBH neurons.
ͺ
ơǤ !e DBH-IR neurons were signi#cantly 
reduced by microinjection of anti-DBH-SAP, compared to control blank-SAP, into the NTS (14 ± 2 in anti-DBH 
SAP group vs. 34 ± 2 in blank-SAP group, p < 0.01) (Fig. 7A–C). !e depressor e"ect of 4V injection of liraglutide 
was attenuated in anti-DBH-SAP injected SHR, as compared to that in control blank-SAP injected SHR (∆MAP 
0.7 ± 2.1 mmHg in anti-DBH-SAP injected group vs. −5.8 ± 1.4 mmHg in control group) (Fig. 8A–C). !e anti-
hypertensive e"ect of repeated LV injection of liraglutide during 14 days was also attenuated in anti-DBH-SAP 
injected group compared to control group (Fig. 8D).
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Figure 3. Repeated LV liraglutide induces c-Fos expression in AP and NTS. Distribution of c-Fos expression 
in the brain of SHR and WKY rats at four hours a&er LV injection of liraglutide on the #rst day of experiment 
(A–G, n = 5) and on the next day a&er termination of repeated LV injection of liraglutide for two weeks (H–N, 
n = 6–7). (A–F,H–M) c-Fos immunostaining in PVN, ARC and AP/NTS a&er LV injection of saline (le& panel) 
or 0.9 µg liraglutide (right panel). Scale bars indicate 200 µm. 3V, third ventricle; CC, central canal. (G,N) 
Number of c-Fos immunoreactive (IR) neurons/section in PVN, SON, ARC, AP, NTS, RVLM and CVLM a&er 
injection of 0.9 µg liraglutide or saline. Each bar represents mean ± SE. *P < 0.05, **P < 0.01 between liraglutide 
and saline, #P < 0.05, ##P < 0.01 between SHR with liraglutide and WKY with liraglutide.
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We have shown that repeated LV injection of liraglutide once a day for 15 days counteracted the development 
of hypertension in SHR, suppressed the norepinephrine excretion, and induced c-Fos expressions in NTS DBH 
neurons. Fourth ventricular injection of liraglutide transiently decreased BP in anesthetized SHR and this e"ect 
was attenuated a&er lesion of NTS DBH neurons by treating with anti-DBH-SAP. In this anti-DBH-SAP injected 
SHR, the antihypertensive e"ect of repeated LV liraglutide was also attenuated. !is study indicates that sustained 
GLP-1R activation in CNS decreases BP via activation of NTS DBH neurons and suppression of sympathetic 
nerve activity in SHR.
!e #rst LV injection of liraglutide increased c-Fos expression in the PVN and ARC in hypothalamus and the 
AP and NTS in brainstem. !is result is in agreement with previous reports30,31. In contrast, following repeated 
LV injection of liraglutide for 14 days, subsequent LV injection of liraglutide enhanced c-Fos expression in the AP 
and NTS but failed to do so in the PVN and ARC. It is noted that c-Fos expression in AP and NTS was increased 
in SHR to a 2-fold greater extent than in WKY rats a&er repeated LV injection of liraglutide for 14 days. !us, 
induction of c-Fos in AP and NTS coincided with a suppression of norepinephrine excretion and counteraction 
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Figure 4. Repeated IP liraglutide induces c-Fos expression in AP and NTS. Distribution of c-Fos expression in 
the brain of SHR at four hours a&er intraperitoneal (IP) injection of liraglutide on the #rst day of experiment 
(A–D, n = 5) and on the next day a&er termination of repeated IP injection of liraglutide for two weeks (E–H, 
n = 5). (A–C,E–G) c-Fos immunostaining in PVN, ARC and AP/NTS a&er IP injection of saline (le& panel) 
or 90 µg/kg liraglutide (right panel). Scale bars indicate 200 µm. 3V, third ventricle; CC, central canal. (D,H) 
Number of c-Fos-IR neurons/section in PVN, SON, ARC, AP, NTS, RVLM and CVLM a&er injection of 
liraglutide or saline. Each bar represents mean ± SE. *P < 0.05, **P < 0.01 between liraglutide and saline.
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of hypertension in SHR. !ese #ndings suggest that the greater activation of AP and NTS by central GLP-1R 
agonism could exert antihypertensive e"ect in the disease condition with excessive sympathoexcitation in SHR. 
Moreover, administration of liraglutide into 4V, an area with an easy access to AP and NTS, decreased BP tran-
siently. !ese results suggest that the AP and/or NTS are the possible target sites for antihypertensive e"ect of 
liraglutide. Furthermore, the current study is the #rst to demonstrate that the sites of c-Fos expression by LV 
liraglutide injection partly change a&er repeated LV injection of liraglutide for 14 days.
In the present study, both before and a&er repeated LV injection of liraglutide, LV injection of liraglutide 
preferentially activated NTS DBH neurons. !is result is in agreement with previous report that LV injection 
of GLP-1R agonist, exendin-4 increased expression of DBH in the NTS32. Moreover, we found that the lesion of 
NTS DBH neurons by treating with anti-DBH-SAP attenuated both the acute depressor e"ect of the 4V injected 
liraglutide and chronic antihypertensive e"ect of the repeated LV injected liraglutide. !ese results suggest that 
liraglutide activates NTS DBH neurons to induce antihypertensive e"ect. Whether liraglutide directly activates 
NTS DBH neurons remains to be determined. It was reported that $uorescence-labeled liraglutide administered 
peripherally could reach the brain through blood-brain barrier and its binding was observed in the AP but not 
NTS21. !is #nding suggests that peripheral liraglutide may not directly interact with the NTS. Our and previous 
#ndings collectively indicate that icv liraglutide may directly act on AP and subsequently lead to activation of 
NTS DBH neurons accompanied by antihypertensive e"ect. Further investigations are required to de#nitively 
elucidate the central neural pathway for the antihypertensive GLP-1 e"ect.
In previous reports, acute administration of GLP-1 and GLP-1R agonist transiently increase BP in normo-
tensive and hypertensive subjects4,9,31. !e possible underlying mechanisms involve central cholinergic system33, 
neurohypophysial hormones33,34 and medullary catecholamine neurons31. In contrast, long-term treatment with 
GLP-1R agonist decreases BP in hypertensive subjects4,8–10. !us, acute and long-term e"ects of GLP-1R ago-
nist are opposite in literatures, while underlying mechanism is unclear. In the present study, according to the 
c-Fos experiments, the initial LV injection of liraglutide activated the hypothalamic PVN and ARC as well as 
the brainstem AP and NTS, whereas the LV injection of liraglutide a&er treatment with liraglutide for 14 days 
failed to activate the hypothalamic PVN and ARC while continuously activating the AP and NTS. !us, acute 
action of GLP-1R agonist to transiently increase BP is apparently paralleled with the initial activation of PVN 
and ARC. !e activation of the PVN parvocellular neurons projecting the intermediolateral cell column directly 
or via RVLM increases sympathetic nerve activity35,36. In addition, some neuropeptides in the PVN such as 
corticotropin-releasing hormone, nesfatin-1 and vasopressin have pressor e"ect37,38. Recently, it was reported that 
PVN speci#c GLP-1R de#ciency attenuated stress-induced ACTH and corticosterone release and cardiovascular 
responses, associated with decreased sympathetic drive to the heart39. !e activation of the melanocortin systems 
in the ARC also increases sympathetic nerve activity and in$uences BP40–43. !us, it is plausible that the transient 
increase in BP by acutely administered GLP-1 and GLP-1R agonist is due to the activation of hypothalamic PVN 
and ARC. !is hypothesis is supported by one previous report that GLP-1 injected into 3V, an area with easy 
access to ARC and PVN, increases BP44.
We have shown that the sustained GLP-1R activation in the CNS decreased the sympathetic nerve activ-
ity and counteracted hypertension, in which the activation of the AP and NTS DBH neurons could be impli-
cated. Recently another group reported that GLP-1 hyperpolarized the bulbospinal RVLM neurons using whole 
cell patch-clamp technique and all the GLP-1-hyperpolarized RVLM neurons showed immunoreactivity for 
GLP-1R45. !is study suggests that GLP-1 may directly act on RVLM neurons to decrease the sympathetic nerve 
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activity and reduce BP. !is report and our current study taken together, the central mechanisms for antihyper-
tensive e"ect of GLP-1R agonist may include central GLP-1 action via the AP and NTS pathway and directly on 
the RVLM. !ese results by us and others suggests that the activation of GLP-1R in the brainstem is crucial for the 
antihypertensive e"ect of central GLP-1.
In the current study, LV liraglutide did not a"ect SBP in early phase of treatment but decreased SBP at 15 days 
of treatment. !e underlying mechanism is unclear but may include the di"erent e"ects of GLP-1R agonist on 
the hypothalamus versus brainstem. We showed acute depressor e"ect of 4V liraglutide mediated by NTS DBH 
neurons and acute activation of NTS DBH neurons a&er LV injection of liraglutide. In acute phase of treatment, 
LV liraglutide also activated the hypothalamic PVN and ARC in addition to NTS DBH neurons. !e pressor 
e"ects induced by activation of PVN and ARC could counterbalance the depressor e"ect induced by activation of 
NTS DBH neurons. !is hypothesis is consistent with the observation at 15 days of liraglutide treatment that LV 
liraglutide decreased SBP in SHR in parallel with the markedly diminished activation of the hypothalamic PVN 
and ARC and sustained activation of the NTS DBH neurons.
In the current study, the expression of endothelial nitric oxide synthase (eNOS) mRNA in the kidney cortex 
of SHR was increased a&er repeated icv injection of liraglutide for 14 days (Fig. S1A). !is result suggests that 
the eNOS-mediated attenuation of peripheral vascular resistance may underly the antihypertensive e"ect of cen-
tral liraglutide. It has been reported that several reagents exert antihypertensive e"ect via activation of eNOS in 
SHR46–49. !ere could be an interaction between the eNOS expression and sympathetic nervous system through 
in$ammatory immune system. Activation of the sympathetic nervous system innervating the bone marrow, 
spleen and peripheral lymphatic systems increases in$ammatory cytokines and decreases endothelial progenitor 
cells, thereby causing vascular endothelial dysfunction to induce hypertension50–53. !ese in$ammatory cytokines 
and endothelial progenitor cells are the factors that regulate the eNOS expression54. !erefore, activation of sym-
pathetic nervous systems could decrease the expression of eNOS and exaggerate the hypertension. However, 
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**P < 0.01 between liraglutide and saline.
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opposite results have also been reported. !e limb ischemia-activated sympathetic nervous system increases 
endothelial progenitor cells in bone marrow via eNOS activation55,56. N(omega)-nitro-L-arginine methyl eater 
(L-NAME), a nonselective NOS inhibitor, reduces renal norepinephrine release induced by renal nerve stimula-
tion in wild type mice but not eNOS knock out mice57. !ese studies suggest that the role of sympathetic nervous 
system in regulating eNOS expressions might vary depending on speci#c disease conditions and on acute vs. 
chronic nature of stimulus. On the other hand, there seems to be a consensus that neuronal NOS (nNOS) has a 
sympathoinhibitory e"ect by acting on di"erent sites of the nervous system including nerves in the kidney58,59. In 
current study nNOS mRNA in the kidney cortex of SHR was not changed by treatment with liraglutide (Fig. S1B), 
suggesting that sympathoinhibitory e"ect of LV liraglutide is not likely due to interaction with nNOS expression 
in the kidney. Further investigations are needed to clarify the contribution of NOS expressions in the kidney to 
the antihypertensive and sympathoinhibitory e"ects mediated by the liraglutide-activated NTS DBH neurons.
It has been shown that administration of GLP-1 or GLP-1R agonist reduces food intake and body weight 
(BW)60–63. Several clinical studies in obesity patients have reported the association between weight loss and reduc-
tion of BP. In some clinical trial in type 2 diabetic patients with overweight or obesity (body mass index ≥25 kg/
m2), 1-year weight loss of 10% or more was associated with a signi#cant reduction of SBP, around 5 mmHg 
through 4 years64. In an analysis of eight clinical trials in type 2 diabetic patients with obesity (body mass index 
at baseline: 31.5 ± 5.6 kg/m2), the treatment with GLP-1R agonist, exenatide decreased SBP of −5.8 ± 0.7 mmHg 
in the patients with greater weight loss of −7.0 ± 0.2 kg from baseline, while decreased SBP of −0.5 ± 0.6 mmHg 
in the patients with smaller weight loss or gain of +1.5 ± 0.1 kg65. In our study, weight gain was smaller with 
liraglutide than saline at 7 days (∆BW + 8.92 g in liraglutide group vs. +16.74 g in control group, p < 0.05) and 
at 14 days (∆BW + 21.51 g in liraglutide group vs. +29.87 g in control group, p < 0.05). Hence, it is possible that 
lesser weight gain partly contributed to the antihypertensive e"ect of repeated icv injection of liraglutide. To 
assess this possibility, we performed a pair feeding study in which food intake in control saline-injected SHR 
was restricted to the level in liraglutide-injected SHR. SBP and urinary norepinephrine excretion in the pair-fed 
saline-injected SHR signi#cantly increased during 14 days, and repeated LV liraglutide injection counteracted 
the development of hypertension (Fig. 1C) and hyper-excretion of urinary norepinephrine at 14 days (Fig. 2B) 
to the extents comparable to those in SHR without pair feeding (Figs 1A and 2A). However, we couldn’t exclude 
possible in$uence of the BW, because weight gain was still smaller with liraglutide than saline with pair feeding 
at 14 days (∆BW + 33.58 g in liraglutide group vs. +38.82 g in pair feeding vehicle group, p < 0.05). Nevertheless, 
the contribution of lesser weight gain to antihypertensive e"ect of liraglutide may be relatively small, since BW 
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was increasing although weight gain was slower with liraglutide. Furthermore, the magnitude of counteraction 
against increase in SBP by −39 mmHg (179 ± 2 mmHg vs. 218 ± 13 mmHg) appears to be much greater than that 
expected from the attenuated weight gain, in view of the quantitative association between weight loss and BP 
reduction in previous reports64,65.
In the current study, repeated LV injection of liraglutide for 15 days did not a"ect the HR measured 4 hours 
a&er LV injection of liraglutide. It was reported that HR was increased by 20 bpm 30 min a&er LV injection of 
GLP-1 and by 60 bpm 2 hours a&er LV injection of exendin-431,33. Another study reported that HR was increased 
1 and 2 hours a&er IP injection of liraglutide, and this response disappeared a&er 3 hours16. Moreover, recent 
study revealed that the chronotropic e"ect of IP injection of liraglutide was diminished in mice with cardio-
myocyte speci#c de#ciency of GLP-1R, and GLP-1R in the heart interacted with autonomic nervous system to 
regulate HR66. !ese reports investigated acute e"ect of initial GLP-1 or GLP-1R agonist injection on HR. Hence, 
the di"erent results between our and previous studies could re$ect the di"erent time points investigated and/or 
the di"erence between repeated and initial injection of GLP-1 or GLP-1R agonist. Furthermore, in our study 4V 
injection of liraglutide did not a"ect HR in the time scale of minutes in anesthetized rats, whereas it was reported 
that 4V injection of exendin-4 increased HR for several hours with peak at 6.5 hours a&er administration in 
non-anesthetized free moving rats67. !ese di"erent experimental conditions may have caused di"erent results.
!ere are several limitations in current study. First, we did not perform direct recording of sympathetic 
nerve activity in both acute and chronic treatment with liraglutide. Whether acute depressor e"ect of 4V injec-
tion of liraglutide is accompanied with decreased sympathetic nerve activity has not been determined yet. We 
assessed urinary norepinephrine excretion as a marker for systemic sympathetic nerve activity under chronic 
treatment with liraglutide. Previous reports suggest a tight correlation between urinary norepinephrine level 
and sympathetic nerve activity recorded in muscle, kidney and lumber in several disease conditions68–71. Based 
on this relationship, urinary norepinephrine has been widely used as a reliable marker for sympathetic nerve 
activity and hence also used in current study. Second, we measured BP indirectly by tail-cu" method instead of 
telemetry method that has been shown to accurately monitor blood pressure in long-term studies72,73. Tail-cu" 
method-induced restrained stress a"ecting BP cannot be eliminated completely. However, in current study 
tail-cu" method without heating was used to avoid thermal stress and rats were habituated to the procedure for 
7 days before experiment to minimize the circumstantial stress. !ere are several reports showing that BP meas-
ured by tail-cu" method is strongly correlated with that by telemetry method and with that by simultaneous arte-
rial catheter method in rodents including SHR used in current study74–76. Hence, we considered that assessment 
of chronic e"ect of liraglutide on BP in SHR in current study is acceptable.
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Figure 8. Lesion of NTS DBH neurons attenuates acute depressor e"ect of 4V liraglutide and chronic depressor 
e"ect of LV liraglutide. Original recordings of the e"ect of 4V injection of liraglutide on blood pressure in 
SHR treated with blank-SAP (A) or anti-DBH-SAP (B). (C) !e peak depressor change in average of MBP 
a&er 4V injection of liraglutide was signi#cantly attenuated in SHR treated with anti-DBH-SAP (n = 5). (D) 
!e antihypertensive e"ect of repeated LV liraglutide at 2 wks was signi#cantly attenuated in SHR treated with 
anti-DBH-SAP (n = 5). Each bar represents mean ± SE. *P < 0.05 between anti-DBH-SAP and blank-SAP 
by unpaired Student’s t test (C) and repeated measures two-way ANOVA followed by Turkey’s post hoc test 
(D). Figure D: P value for time, group and time x group interaction are p = 0.0003, p = 0.2989 and p = 0.0073, 
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1 0SCIENTIFIC REPORTS |         (2019) 9:12986  | ǣȀȀǤȀͷͶǤͷͶ͹;ȀͺͷͻͿ;ǦͶͷͿǦͺͿ͹ͼͺǦ
www.nature.com/scientificreportswww.nature.com/scientificreports/
In conclusion, we have demonstrated that long-term central treatment with GLP-1R agonist attenuates the 
development of hypertension via mechanisms involving the activation of brainstem DBH neurons and suppres-
sion of sympathetic nerve activity in SHR. Both peripheral and central injection of liraglutide increased c-Fos 
expression in the same area of the brain in SHR. !ese results suggest that the activation of speci#c brain areas 
by central GLP-1R agonist demonstrated in current study may underlie the e"ects reported in the recent clinical 
studies that treatment with GLP-1R agonists signi#cantly reduced BP and cardiovascular events in type-2 dia-
betic patients1–3. Furthermore, we showed the antihypertensive e"ect of GLP-1R agonist in addition to and inde-
pendently of well-established anti-diabetic and anti-obese e"ects, suggesting that GLP-1R agonist is bene#cial 
especially to the hypertensive patients with diabetes and/or obesity.

Ǥ Male SHR and control WKY rats aged 6 weeks (Hoshino Laboratory Animals, Ibaraki, Japan) were 
maintained on a 12 h light/dark cycle (19:30 light o") and given conventional food (CE-2; Clea, Osaka, Japan) 
and water ad libitum. All animal procedures were conducted in compliance with protocols approved by Jichi 
Medical University Animal Care and Use Committee, and all experiments were carried out in accordance with 
the approved protocols.
Ǥ Rats were anesthetized by IP injection of Avertin (tribromoeth-
anol, 200 mg/kg, ip). A stainless steel guide cannula (26-gauge) was stereotaxically inserted into LV (0.8 mm 
caudal to the bregma, 1.5 mm lateral from midline and 3.2 mm below the surface of the skull). !e injector needle 
extended 0.6 mm below the guide cannula. Rats were allowed to recover from the operation for 10 days while they 
were habituated to handling. Liraglutide (Novo Nordisk Pharma Ltd., Tokyo, Japan) 0.9 µg/3 µl dissolved in vehi-
cle (saline; 0.9% NaCl) or 0.9% NaCl 3 µl (vehicle) was injected once a day for 15days. SBP and HR were measured 
using a tail-cu" system (Model MK-2000, Muromachi Co. Ltd., Tokyo, Japan) in conscious rats 4 hours a&er LV 
injection of liraglutide or vehicle, and the measurements were performed every three days up to 15 days in SHR 
and at 1 and 2 weeks in WKY rats. Rats were allowed to habituate to the procedure for 7 days before experiments 
were performed. SBP and HR values were averaged from the three consecutive recordings obtained from each 
rat. At the end of the experiments, sections of the forebrain were histologically examined to verify the position of 
the cannulas. !e rats in which cannulas were outside LV were excluded from the data analysis. For pair-feeding, 
the amount of food consumed by the liraglutide-treated group over the course of 24 h was measured at 9:00, and 
a corresponding amount of pellets was given to the pair-fed group over a 24-h period. !e food intake over 24 h 
was calculated by weighing the remaining food pellets every day. SBP and HR were measured as mentioned above 
in the pair-fed SHR at 1 and 2 weeks.
ǡͺǤ A separate group of rats were used to 
assess the consequences of lesions of NTS DBH neurons on changes in blood pressure by 4V injection of liraglu-
tide. Rats were anesthetized with avertin (200 mg/kg, IP). Glass micropipettes #lled with blank-SAP (Advanced 
Targeting Systems, San Diego, CA) 6 ng/200 nl or anti-DBH-SAP (Advanced Targeting Systems, San Diego, CA) 
40 ng/200 nl dissolved in saline were stereotaxically placed into the NTS (12.5 mm caudal to the bregma, 0.5 mm 
lateral from midline and 8.9 mm below the surface of the skull). Microinjections were made bilaterally. A total 
volume (200 nl) of injection was made over 2 min a&er which the pipette was le& in place for additional 10 min 
to prevent re$ux of $uid from the pipette track. For 4V injection, the cannula was placed stereotaxically into the 
4V (11.5 mm caudal to the bregma, in the midline and 8.6 mm below the surface of the skull) and the position of 
cannula was histologically veri#ed at the end of the experiment as described above. Two weeks a&er NTS micro-
injection of saporin, 4V cannulated rats were anesthetized with urethane (1.0 g/kg, IP). !e le& femoral artery 
was cannulated, and the arterial line was connected to a pressure transducer (Ampli#er Case 7903, Sanei Cardio 
Co. Ltd., Tokyo, Japan) for data recording and analysis (LabScribe2, Worx Systems Inc., Dover, NH) of BP and 
HR. !en rats were placed in a stereotaxic apparatus in a prone position, and BP and HR were monitored a&er 4V 
injection of liraglutide (0.9 µg/3 µl).
Ǧ	Ǥ Immunohistochemistry for c-Fos and DBH were per-
formed a&er LV injection of liraglutide (0.9 µg/3 µl) and IP injection of liraglutide (90 µg/kg). Four hours a&er 
injection of liraglutide or saline, rats were anesthetized with iso$urane and perfused transcardially saline con-
taining heparin (20 U/ml) for 3 min and then 4% paraformaldehyde in 0.1 M phosphate bu"er (PB) containing 
0.2% picric acid for 20 min. !e brains were removed and post#xed in the same #xative for 1 h and in 0.1 M PB 
containing 15% sucrose overnight at 4 °C. !ey were then transferred to 30% sucrose solution in 0.1 M PB for 2 
days. !e brains were embedded in Tissue-Tek OCT compound (Sakura Finetechnical Co. Ltd., Tokyo, Japan) 
and frozen on dry ice and kept at −80 °C until sectioning. Coronal sections with 40 µm thickness were cut with 
a freezing microtome and collected at 160 µm intervals. Sections were rinsed in phosphate bu"ered saline (PBS) 
and then incubated in 0.3% H2O2 for 20 min. A&er rinsing, sections were blocked with 2% bovine serum albu-
min and 2% normal goat serum for 30 min and incubated with rabbit anti-c-Fos antibody (Ab-5; Calbiochem, 
San Diego, CA; 1:2000) overnight at 4 °C. !en the sections were rinsed and incubated with biotinylated goat 
anti-rabbit IgG for 30 min. A&er rinsing, sections were incubated with avidin-biotin complex (ABC) reagent for 
30 min (Vector Laboratories; 1:500). A&er rinsing in PBS, color was developed with a nickel-diaminobenzidine 
(DAB) solution (0.3% nickel ammonium sulfate, 0.02% DAB, and 0.005% H2O2 in 0.05 M Tris bu"er) for 5 min. 
For double-labeling immunohistochemistry for c-Fos with DBH, the process of DBH staining was added. A&er 
rinsing in PBS, sections were treated with an avidin and biotin blocking solution (Vector Laboratories) and 
then incubated with mouse anti-DBH antibody (MAB308; Millipore, Billerica, MA, 1:500) diluted in a blocking 
solution overnight at 4 °C. A&er rinsing, sections were incubated with biotinylated goat anti-rabbit antibody 
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for 30 min and incubated in ABC reagent for 30 min. !en the sections were rinsed in PBS and Tris bu"er, and 
color was developed with a DAB solution (0.02% DAB and 0.005% H2O2 in Tris bu"er). Slices were then rinsed, 
mounted on slides, and coverslipped with Entellan new (Merck, Darmstadt, Germany).
!e number of c-Fos-IR and DBH-IR cells per section were counted in PVN, supraoptic nucleus (SON) and 
ARC between −1.3 and −3.3 mm or in NTS, RVLM and caudal ventrolateral medulla (CVLM) between −12.3 
and −14.3 mm from bregma. For double immunostaining, c-Fos-IR cells, DBH-IR cells, and dually IR cells were 
counted in the sections containing NTS between −13.3 and −14.3 mm from bregma. Cell counting was con-
ducted using Find Maxima function in ImageJ so&ware (NIH), which was validated by manual counting of IR 
cells. !ree to #ve sections were averaged for each rat. !e fraction of c-Fos-IR cells in DBH-IR cells, expressed as 
percentage, was averaged for all sections.
Ǥ Urinary norepinephrine excretion was measured as 
an index of overall sympathetic activity at 2 weeks of repeated administration of liraglutide or vehicle. Urine sam-
ples were collected with the metabolic cages KN-649 (Natsume Co. Ltd., Tokyo, Japan) for 24 h using the 50-ml 
collecting tubes contained 6N HCl to prevent the autooxidation of catecholamines. !e urinary norepinephrine 
concentrations were measured with high-performance liquid chromatography (SRL Inc., Tokyo, Japan).
ǦǤ Kidney cortex 
was excised from the le& and right sides under anesthesia with iso$urane. Total RNA was isolated using TRIzol 
(Invitrogen, Madison, WI) and treated with RQ1-DNase (Promega, Madison, WI). First-strand cDNA synthesis 
was completed using ReverTra Ace kit (Toyobo, Osaka, Japan). Quantitative RT-PCR assay was performed using 
SYBR Premix Ex Taq II polymerase in !ermal Cycler Dice (Takara Bio, Tokyo, Japan). Expression levels of 
mRNAs were calculated by the ∆∆CT method of relative quanti#cation, and corrected by 18 S Ribosomal RNA. 
!e base sequences of primers used are as follows.
Rat eNOS:                     forward;   5′-AGCTGGATGAAGCCGGTGAC-3′
reverse; 5′-CCTCGTGGTAGCGTTGCTGA-3
Rat nNOS:                     forward;  5′-CCTATGCCAAGACCCTGTGTGA-3′
reverse; 5′-CATTGCCAAAGGTGCTGGTG-3′
18S ribosomal RNA: forward; 5′-TTCGAACGTCTGCCCTATCAA-3′
reverse; 5′-ATGGTAGGCACGGCGACTA-3′.
Ǥ Data are expressed as means ± S.E. Scatter plot was included in several bar graphs. Data 
were analyzed by unpaired or paired Student’s t test or by one-way or repeated measures two-way ANOVA with 
treatment (saline vs. liraglutide) and time as factors. Post hoc multiple comparisons were made using Turkey’s 
post hoc test. P < 0.05 was considered signi#cant.
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